Completed PHASE3 INTERVENTIONAL NCT00002140

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

Sponsor: Pfizer

Conditions HIV Infections Mycobacterium Avium-intracellulare Infection

Interventions Azithromycin Clarithromycin Ethambutol hydrochloride

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV Infections and Mycobacterium Avium-intracellulare Infection, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Austin, United States , Berkeley, United States , Chicago, United States , Dallas, United States , Durham, United States , Groton, United States , Hampton, United States , Houston, United States , Kansas City, United States and 10 more locations